App-Quantinova.ai

Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.

Libor Havel - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxychloroquine

Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study.

Leonard Joseph Appleman - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Hydroxychloroquine

A pilot, phase I clinical trial to determine the biological effects of hydroxychloroquine (HCQ) on par-4 levels in patients with surgically removable solid tumors.

Peng Wang - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxychloroquine

Modulation of autophagy with hydroxychloroquine in patients with advanced non-small cell lung cancer (NSCLC): A phase Ib study.

Jyoti Malhotra - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxychloroquine

Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.

Mark H. O'Hara - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxychloroquine

Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC).

Theodore S. Hong - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxychloroquine

A physiologically-based pharmacokinetic (PBPK) model of hydroxychloroquine

Keagan P. Collins - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxychloroquine

A novel nanoparticle formulation of doxorubicin is clearly differentiated from free doxorubicin in overcoming resistance mechanisms in chemo-resistant tumors

Veronique Trochon-joseph - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxychloroquine

Inhibition of ribosomal protein S6 (rpS6) phosphorylation and cell proliferation by a novel chloroquine analog in lung cancer cells

Juan Sironi - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxychloroquine

Influence of autophagy modulation on synergistic interactions of lapatinib and mTOR targeted agents in HER2-amplified lapatinib resistant breast cancer models in vitro and in vivo

Wieslawa H. Dragowska - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Hydroxychloroquine

Expression pattern of ALDH1A1 and HLTF predicts sensitivity to lysosomal autophagy inhibitors in cancer cells

Shengfu Piao - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Hydroxychloroquine

Structural features of novel dimeric quinacrines that have single-agent antitumor activity determine the mechanism of action: destabilization of mTORC1/lysosomal interaction versus DNA damage

Vito W. Rebecca - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

Hydroxychloroquine

Lipid-based nanoparticulate hydroxychloroquine (HCQ) formulations for use in combination with autophagy inducing drugs for treatment of breast cancer

Jagbir Singh - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Hydroxychloroquine

Pharmacokinetic and pharmacodynamic assessment of autophagy inhibition following hydroxychloroquine in mice

Kristen M. Jackson - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Hydroxychloroquine

Immunotherapy targeting folate receptor induces autophagy in ovarian cancer

Yun-Fei Wen - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High grade serous ovarian cancer

Hydroxychloroquine

Compound Tc inhibits ATG4 to attenuate autophagic flux and sensitize cancer cells to chemotherapy

Chih-Wen Shu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Hydroxychloroquine

A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).

Joel W. Neal - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Hydroxychloroquine

A phase I trial of MK-2206 and hydroxychloroquine(HCQ) in solid tumors, melanoma, renal, and prostate cancer to examine the role of autophagy in tumorigenesis.

Amanda D. Kaveney - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Hydroxychloroquine

Mesalazine and cigarette smoke inhibit neutrophil extracellular trap formation in vitro

N. Sinnem - European Crohn’s and Colitis Organisation (ECCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Twin-reversed arterial perfusion

Hydroxychloroquine

Neuroblastoma Stem Cells: Identifying Two New Classes of Drugs with in-Vitro Activity in Cell Populations with High Side-Population Profiles

Don W Coulter - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

Hydroxychloroquine

Filters

1151 Abstracts